2.61
+0.02(+0.77%)
Currency In USD
| Previous Close | 2.59 |
| Open | 2.64 |
| Day High | 2.67 |
| Day Low | 2.42 |
| 52-Week High | 3.83 |
| 52-Week Low | 0.22 |
| Volume | 4.67M |
| Average Volume | 10.92M |
| Market Cap | 191.76M |
| PE | -3.95 |
| EPS | -0.66 |
| Moving Average 50 Days | 1.19 |
| Moving Average 200 Days | 0.65 |
| Change | 0.02 |
If you invested $1000 in Cognition Therapeutics, Inc. (CGTX) since IPO date, it would be worth $204.39 as of September 08, 2025 at a share price of $2.61. Whereas If you bought $1000 worth of Cognition Therapeutics, Inc. (CGTX) shares 3 years ago, it would be worth $1,359.38 as of September 08, 2025 at a share price of $2.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target
GlobeNewswire Inc.
Sep 03, 2025 11:30 AM GMT
PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study h
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
GlobeNewswire Inc.
Sep 02, 2025 8:00 PM GMT
PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced regist
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Aug 28, 2025 12:53 AM GMT
- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders - PURCHASE, N.Y., Aug. 27, 2025 (GLOBE